AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33785196 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access to physiotherapy services
Number of subjects: 10000
Study 33785196 — intervention group
Group type: COMPARATOR
Intervention: Traditional GP-referral to NHS physiotherapy
Number of subjects: 10000
Study 33334450 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Dobutamine (DBT) (40 to 50 μg/kg/min for 10 min)
Number of subjects: 50
Study 33334450 — intervention group
Group type: COMPARATOR
Intervention: High-dose Isoproterenol (IPN) (20 to 30 μg/min for 10 min)
Number of subjects: 50
Study 35560162 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected breast cancer screening
Number of subjects: 79354
Study 35560162 — intervention group
Group type: COMPARATOR
Intervention: Clinically detected breast cancer screening
Number of subjects: 79354
Study 35560162 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program (both modalities)
Number of subjects: 79354
Study 33592825 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified selective spinal massage method combined with basic rehabilitation treatment
Number of subjects: 182
Study 33592825 — intervention group
Group type: COMPARATOR
Intervention: Basic rehabilitation treatment
Number of subjects: 182
Study 35689890 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2000 mg/d)
Number of subjects: 58
Study 35689890 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2000 mg/d) in male participants
Number of subjects: 58
Study 35689890 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2000 mg/d) in female participants
Number of subjects: 58
Study 33075197 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sinecatechins ointment applied three times daily for 16 weeks
Number of subjects: 26
Study 33075197 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment applied three times daily for 16 weeks
Number of subjects: 26
Study 32729407 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized vagus nerve massage
Number of subjects: 60
Study 32729407 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized soft shoulder massage
Number of subjects: 60
Study 32729407 — intervention group
Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 60
Study 36042484 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 298
Study 36042484 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane inhalation
Number of subjects: 298
Study 34417989 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0
Study 34417989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32250336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training at 60‐80% of heart rate reserve
Number of subjects: 22
Study 32250336 — intervention group
Group type: COMPARATOR
Intervention: Outdoor-overground walking below 40% of heart rate reserve
Number of subjects: 22
Study 36432526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33887445 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful isometric shoulder exercises (external rotation; 20% above pain threshold)
Number of subjects: 35
Study 33887445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpainful isometric shoulder exercises (external rotation; 20% below pain threshold)
Number of subjects: 35
Study 33887445 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 35
Study 32899037 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 or 15 mg twice daily (BID)
Number of subjects: 239
Study 32899037 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg BID
Number of subjects: 239
Study 32899037 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin (flexible dosing)
Number of subjects: 239
Study 34957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic covariate adjustment using historical data
Number of subjects: 0
Study 34957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic models that explain a clinically realistic percentage of the outcome variance
Number of subjects: 0
Study 33070988 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy
Number of subjects: 0
Study 33070988 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers (fecal calprotectin)
Number of subjects: 0
Study 33070988 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological healing
Number of subjects: 0
Study 35078545 — intervention group
Group type: EXPERIMENTAL
Intervention: VR Blue (30-min virtual underwater/sea environment)
Number of subjects: 20
Study 33856487 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional advertising channels
Number of subjects: 160
Study 33856487 — intervention group
Group type: EXPERIMENTAL
Intervention: Instagram advertising
Number of subjects: 160
Study 36472718 — intervention group
Group type: EXPERIMENTAL
Intervention: Square-wave insulin bolus (SQ)
Number of subjects: 58
Study 34140179 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized SMS text-message-based weight loss intervention
Number of subjects: 80
Study 34140179 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 80
Study 36448347 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional prenatal health mission combined with desktop VR health education system mode
Number of subjects: 200
Study 36448347 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education mode
Number of subjects: 200
Study 33445223 — intervention group
Group type: EXPERIMENTAL
Intervention: DIDP scale
Number of subjects: 1578
Study 33445223 — intervention group
Group type: EXPERIMENTAL
Intervention: ADDQoL-19 scale
Number of subjects: 1578
Study 33445223 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes QoL-Q scale
Number of subjects: 1578
Study 33445223 — intervention group
Group type: EXPERIMENTAL
Intervention: DSQOLS scale
Number of subjects: 1578
Study 33445223 — intervention group
Group type: EXPERIMENTAL
Intervention: DCP scale
Number of subjects: 1578
Study 32007123 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) applied post-surgery, maintaining negative pressure at -125 mmHg for five days.
Number of subjects: 19
Study 32007123 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressings (SSD) as a comparison to NPWT.
Number of subjects: 19
Study 32755035 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 43
Study 32755035 — intervention group
Group type: COMPARATOR
Intervention: No belimumab (RC group)
Number of subjects: 43
Study 32200266 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oral intake of low-fat solid food (15 g/d)
Number of subjects: 26
Study 32200266 — intervention group
Group type: COMPARATOR
Intervention: Standard food with gradually increasing amounts of dietary fat
Number of subjects: 26
Study 34716211 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Number of subjects: 25
Study 34716211 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine U100
Number of subjects: 25
Study 33836711 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainwork Intervention
Number of subjects: 320
Study 33836711 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 35026964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity ultrasound (LIUS)
Number of subjects: 498
Study 35026964 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound treatment (Control)
Number of subjects: 498
Study 33941624 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic questionnaire with 11 health items
Number of subjects: 0
Study 33941624 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic questionnaire with 44 health items
Number of subjects: 0
Study 33941624 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic questionnaire with 56 health items
Number of subjects: 0
Study 33941624 — intervention group
Group type: COMPARATOR
Intervention: Provider records (gold standard)
Number of subjects: 0
Study 33338325 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal occupational therapy (including patient education, hand exercises, orthoses, and assistive devices)
Number of subjects: 180
Study 33338325 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (OA information)
Number of subjects: 180
Study 35045228 — intervention group
Group type: EXPERIMENTAL
Intervention: SER-109 (four capsules daily for 3 days)
Number of subjects: 182
Study 35045228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four capsules daily for 3 days)
Number of subjects: 182
Study 33051650 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin monotherapy
Number of subjects: 0
Study 33051650 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin with flucytosine
Number of subjects: 0
Study 33051650 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin with fluconazole
Number of subjects: 0
Study 32524497 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidneys from donors with PUJ dysfunction
Number of subjects: 198
Study 32524497 — intervention group
Group type: COMPARATOR
Intervention: Control group (kidneys from donors without PUJ dysfunction)
Number of subjects: 198
Study 35241042 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered HIV self-testing (HIVST) intervention
Number of subjects: 30
Study 34256413 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological ICSI (PICSI)
Number of subjects: 0
Study 34256413 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICSI
Number of subjects: 0
Study 33010038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks (q2w)
Number of subjects: 0
Study 33010038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34264000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model-based intervention (StrokeCARE protocol) for 12 weeks
Number of subjects: 0
Study 34264000 — intervention group
Group type: COMPARATOR
Intervention: Routine patient care (control group)
Number of subjects: 0
Study 33397352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-limb complications (PAD or neuropathy)
Number of subjects: 11140
Study 33397352 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD)
Number of subjects: 11140
Study 33397352 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy
Number of subjects: 11140
Study 33397352 — intervention group
Group type: COMPARATOR
Intervention: No lower-limb complications
Number of subjects: 11140
Study 32700926 — intervention group
Group type: EXPERIMENTAL
Intervention: Countering emotional behaviors module from the unified protocol
Number of subjects: 8
Study 35195914 — intervention group
Group type: EXPERIMENTAL
Intervention: Think Bright training
Number of subjects: 68
Study 35195914 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular training regimen)
Number of subjects: 68
Study 33955183 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 36
Study 33955183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 35276079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride plus olanzapine
Number of subjects: 328
Study 35276079 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride plus placebo
Number of subjects: 328
Study 35276079 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 328
Study 32470147 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sedation
Number of subjects: 0
Study 616774451 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 90
Study 616774451 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.375 mg
Number of subjects: 90
Study 616774451 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 90
Study 32052014 — intervention group
Group type: EXPERIMENTAL
Intervention: DAAs
Number of subjects: 1078
Study 32052014 — intervention group
Group type: COMPARATOR
Intervention: IFN
Number of subjects: 1078
Study 32052014 — intervention group
Group type: COMPARATOR
Intervention: IFN nonresponders
Number of subjects: 1078
Study 33150235 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) awareness and practice education
Number of subjects: 354
Study 35193638 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-donor fecal microbiota (FM) transfer
Number of subjects: 174
Study 35193638 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-donor fecal microbiota filtrates (FMF) transfer
Number of subjects: 174
Study 35193638 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 174
Study 33373048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored mental health literacy training for police members; leadership development and coaching program for station leaders.
Number of subjects: 53
Study 32568876 — intervention group
Group type: EXPERIMENTAL
Intervention: 38°C forced-air warming blankets
Number of subjects: 123
Study 32568876 — intervention group
Group type: COMPARATOR
Intervention: 43°C forced-air warming blankets
Number of subjects: 123
Study 36102236 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exacerbation
Number of subjects: 10355
Study 36102236 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe exacerbation
Number of subjects: 10355
Study 32206786 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month regimen alternating intravenous and oral glucocorticoids with an alkylating agent every other month
Number of subjects: 0
Study 32206786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study 32206786 — intervention group
Group type: COMPARATOR
Intervention: Cyclical therapy (glucocorticoids and alkylating agent)
Number of subjects: 0
Study 32206786 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors
Number of subjects: 0
Study 32206786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate salts and adrenocorticotropic hormone
Number of subjects: 0
Study 34499904 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group (3 g of ampicillin-sulbactam administered just before, 8 hours after, and the morning after ESD)
Number of subjects: 432
Study 34499904 — intervention group
Group type: COMPARATOR
Intervention: Nonantibiotic group (conventional treatment)
Number of subjects: 432
Study 32746956 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Guided Questions Tool
Number of subjects: 82
Study 32746956 — intervention group
Group type: COMPARATOR
Intervention: Original Guided Questions Tool
Number of subjects: 82
Study 35206520 — intervention group
Group type: EXPERIMENTAL
Intervention: KEPT app
Number of subjects: 26
Study 35206520 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care (waitlist control)
Number of subjects: 26
Study 33567185 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide (2.4 mg)
Number of subjects: 1961
Study 33567185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1961
Study 34811841 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy (BBAT)
Number of subjects: 101
Study 34811841 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 101
Study 32279416 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) allele frequency (AF)
Number of subjects: 73
Study 32279416 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA AF, AFP level, and BCLC staging
Number of subjects: 73
Study 36316511 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea 40%
Number of subjects: 21
Study 36316511 — intervention group
Group type: COMPARATOR
Intervention: Fr Er:YAG laser
Number of subjects: 21
Study 33180897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment options for hypertension (HTN)
Number of subjects: 2500000
Study 33180897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment options for type II diabetes mellitus (T2DM)
Number of subjects: 2500000
Study 33180897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative treatment options for hyperlipidemia (HL)
Number of subjects: 2500000
Study 32119883 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Food Test (choice scale)
Number of subjects: 666
Study 32119883 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Food Test (applied knowledge scale)
Number of subjects: 666
Study 32119883 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Food Test (overall choices)
Number of subjects: 666
Study 32119883 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Food Test (subscales)
Number of subjects: 666
Study 32119883 — intervention group
Group type: EXPERIMENTAL
Intervention: Health versus taste motive
Number of subjects: 666
Study 32119883 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control and habitual fruit and vegetable intake
Number of subjects: 666
Study 33359303 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hydrocortisone
Number of subjects: 325
Study 33359303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 32376724 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg orally once daily) plus Camrelizumab (200 mg intravenously every 2 weeks)
Number of subjects: 43
Study 32376724 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus Camrelizumab
Number of subjects: 43
Study 34878650 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (Anakinra)
Number of subjects: 0
Study 34878650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34063970 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device + game-based virtual reality rehabilitation program (30 mins/session, 5 sessions/week, for 4 weeks)
Number of subjects: 44
Study 34063970 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 44
Study 33185373 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block using 25 mg bupivacaine plus 8 mg dexamethasone in a total volume of 10 mL twice one week apart (Group I)
Number of subjects: 80
Study 33185373 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block using 25 mg bupivacaine plus 8 mg dexamethasone in a total volume of 10 mL 3 times one week apart (Group II)
Number of subjects: 80
Study 34996406 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg daily injection
Number of subjects: 17
Study 35590219 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06835919 300 mg
Number of subjects: 53
Study 35590219 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06835919 75 mg
Number of subjects: 53
Study 35590219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 32981554 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) intervention
Number of subjects: 305
Study 32981554 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 305
Study 32981554 — intervention group
Group type: EXPERIMENTAL
Intervention: Coercive measures
Number of subjects: 305
Study 35579454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose
Number of subjects: 149
Study 35579454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 33542908 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-22 mg/kg/d UDCA
Number of subjects: 73
Study 33542908 — intervention group
Group type: COMPARATOR
Intervention: 13-15 mg/kg/d UDCA (standard dosage)
Number of subjects: 73
Study 32548907 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative conditioning with a positive peer context (group games paired with tasting target vegetables)
Number of subjects: 23
Study 32548907 — intervention group
Group type: COMPARATOR
Intervention: Repeated exposure (only taste exposures of target vegetables)
Number of subjects: 23
Study 34556269 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 235
Study 34556269 — intervention group
Group type: COMPARATOR
Intervention: No PCI (control)
Number of subjects: 235
Study 33894583 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete Cosine Transform (DCT) model
Number of subjects: 66
Study 33894583 — intervention group
Group type: COMPARATOR
Intervention: Cosine model (CM)
Number of subjects: 66
Study 33894583 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT model with amplitude variations from CBCTp
Number of subjects: 66
Study 33894583 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT model with baseline shift variability
Number of subjects: 66
Study 32159454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 38
Study 32159454 — intervention group
Group type: COMPARATOR
Intervention: Volumetric measurements
Number of subjects: 38
Study 35485738 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises via telemedicine (three times a day for 5 weeks, one session via telemedicine each week)
Number of subjects: 52
Study 35485738 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises via telemedicine
Number of subjects: 52
Study 35485738 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochure explaining exercises)
Number of subjects: 52
Study 34837744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2)
Number of subjects: 80
Study 34837744 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 6) and paclitaxel (175 mg/m2) without bevacizumab
Number of subjects: 80
Study 32155323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (multicomponent exercise training programme for 5-7 consecutive days, 2 sessions/day)
Number of subjects: 370
Study 32155323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 370
Study 32155323 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 370
Study 35781044 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation (RD)
Number of subjects: 80
Study 35781044 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 80